Purpose: Peeling of the internal limiting membrane (ILM) has improved the outcomes in vitreoretinal surgery of macular diseases. Indocyanine green (ICG) is used to stain and improve the visualization of the ILM. This paper aims to describe a modified approach to stain and peel the ILM avoiding potential adverse side effects. Methods: After a core vitrectomy, 0.05 ml of ICG in a concentration of 5 mg/ml is quickly injected under water around the macular region. The tip of the syringe is positioned about 5 mm from the macular tissue, in a way that about a 3-mm diameter area around the fovea is stained by the ICG. Additional ICG is immediately removed by aspiration. Peeling of the ILM is accomplished with a forceps. Results: Neither residual ICG in the vitreous cavity nor any clinical signs of phototoxicity like retinal edema were detected in any patients operated by this technique. Conclusions: This modified technique to stain the ILM limits the amount and concentration of ICG. The locally limited contact of ICG with the retinal surface seems to be a safe procedure to stain the ILM.

Smiddy WE, Michels RG, de Bustros S, de la Cruz Z, Green WR: Histopathology of tissue removed during vitrectomy for impending idiopathic macular holes. Am J Ophthalmol 1989;108:360–364.
Smiddy WE, Michels RG, Green WR: Morphology, pathology, and surgery of idiopathic vitreoretinal macular disorders: A review. Retina 1990;10:288–296.
Guyer DR, Green WR, de Bustros S, Fine SL: Histopathologic perifoveal tissue dissection in the management of acute idiopathic full-thickness macular holes. Arch Ophthalmol 2000;118:495–498.
Gandorfer A, Messmer EM, Ulbig MW, Kampik A: Resolution of diabetic macular edema after surgical removal of the posterior hyaloid and the inner limiting membrane. Retina 2000;20:126–133.
Park DW, Sipperley JO, Sneed SR, Dugel PU, Jacobsen J: Macular hole surgery with internal-limiting membrane peeling and intravitreous air. Ophthalmology 1999;106:1392–1397.
Eckardt C, Eckardt U, Groos S, Luciano L, Reale E: Entfernung der Membrana limitans interna bei Makulaforamen: Klinische und morphologische Befunde. Ophthalmologe 1997;94:545–551.
Mester V, Kuhn F: Internal limiting membrane removal in the management of full-thickness macular holes. Am J Ophthalmol 2000;129:769–777.
Livingstone BI, Bourke RD: A retrospective study of macular holes with pars plana vitrectomy. Aust NZ J Ophthalmol 1999;27:331–341.
McEnerney JK, Peyman GA: Indocyanine green: A new vital stain for use before penetrating keratoplasty. Arch Ophthalmol 1978;96:1445–1447.
Horiguchi M, Miyake K, Ohta I, Ito Y: Staining of the lens capsule for circular continuous capsulorrhexis in eyes with white cataract. Arch Ophthalmol 1998;116:535–537.
Brooks HL: Macular hole surgery with and without internal limiting membrane peeling. Ophthalmology 2000;107:1939–1948.
Burk SE, Da Mata AP, Rosa RH Jr, Foster RE: Indocyanine green-assisted peeling of the retinal internal limiting membrane. Ophthalmology 2000;107:2010–2014.
Schmidt JC, Meyer CH, Rodrigues EB, Hoerle S, Kroll P: Staining of internal limiting membrane in vitreomacular surgery: A simplified technique. Retina 2003;23:263–264.
Rodrigues EB, Meyer CH, Schmidt JC, Kroll P: Surgical management of epiretinal membrane with indocyanine-green-assisted peeling. Ophthalmologica 2004;218:73–74.
Sorcinelli R: Surgical management of epiretinal membrane with indocyanine-green-assisted peeling. Ophthalmologica 2003;217:107–110.
Gass CA, Haritoglou C, Schaumberger M, Kamplik A: Indozyanin-Grün beeinflusst das funktionelle Ergebnis nach Chirurgie bei Maculaforamen (abstract). Ophthalmologe 2002:S83.
Enaida H, Sakamoto T, Hisatomi T, Goto Y, Ishibashi T: Morphological and functional damage of the retina caused by intravitreous indocyanine green in rat eyes. Graefe’s Arch Clin Exp Ophthalmol 2002;240:209–213.
Weinberger AWA, Kirchhof B, Mazinani BE, Schrage NF: Persistent indocyanine green (ICG) fluorescence 6 weeks after intraocular ICG administration for macular hole surgery. Graefe’s Arch Clin Exp Ophthalmol 2001;239:388–390.
Ciardella AP, Schiff W, Barile G, Vidne O, Sparrow J, Langton K, Chang S: Persistent indocyanine green fluorescence after vitrectomy for macular hole. Am J Ophthalmol 2003;136:174–177.
Ashikari M, Ozeki H, Tomida K, Sakurai E, Tamai K, Ogura Y: Retention of dye after indocyanine green-assisted internal limiting membrane peeling. Am J Ophthalmol 2003;136:172–174.
Da Mata AP, Burk SE, Riemann CD, Rosa RH Jr, Snyder ME, Petersen MR, Foster RE: Indocyanine green-assisted peeling of the retinal internal limiting membrane during vitrectomy surgery for macular hole repair. Ophthalmology 2001;108:1187–1192.
Tornambe PE: ICG-enhanced vitreous surgery: Current concepts; in American Academy of Ophthalmology (ed): Retina: A Retina Odissey 2001. American Academy of Ophthalmology.
Yonemura N, Hirata A, Hasumura T, Negi A: Fundus changes corresponding to visual field defects after vitrectomy for macular hole. Ophthalmology 2001;108:1638–1643.
Kadonosono K, Itoh N, Uchio E, Nakamura S, Ohno S: Staining of internal limiting membrane in macular hole surgery. Arch Ophthalmol 2000;118:1116–1118.
Uemura A, Kanda S, Sakamoto Y, Kita H: Visual field defects after uneventful vitrectomy for epiretinal membrane with indocyanine green-assisted internal limiting membrane peeling. Am J Ophthalmol 2003;136:252–257.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.